BDNF has been reported as a direct target of MeCP2 repression [30,31]; however, its levels are reduced in the brain of RTT patients and Mecp2 mutant mice and treatment with BDNF have been suggested as a therapeutic approach for RTT [32,33]. The gene discussed is BDNF; the disease is Rett syndrome.